24 July 2008
Amyotrophic lateral sclerosis after one-year medication of cannabinoid receptor antagonist: A case of iatrogenic ALS?
Marcello ZannaAm J Case Rep 2008; 9:333-337 :: ID: 865124
Abstract
Background: A cannabinoid (CB) receptor antagonist, rimonabant, is a new promising agent in the treatment of atherosclerosis and other disorders including alcoholism. In experiments, CB receptor agonist protects the onset and progression of neurodegenerative diseases such as amyotrophic lateral sclerosis (ALS), characterized clinically by progressive devastating systemic muscle weakness and atrophy.
Case Report: A 61-year-old woman taking thyroid hormone and calcium after thyroid resection received rimonabant during 12 months for clinical trial of lipid lowering. During the trial, she developed muscle cramps, and a few months later after the end of rimonabant medication, she developed weakness in the both legs, extending progressively systemic muscle weakness and atrophy. One year later, neurological wouk-up including electromyogram and neuroimagings demonstrated both lower and upper motor neuron sings and a cognitive dysfunction of the frontal lobe, indicating a clinical diagnosis of definite ALS. The patient has gradually worsened to ambulatory diffi culty 15 months after the end of rimonabant medication.
Conclusions: This patient may represent the first case having ALS after medication of CB receptor antagonist. The further follow-up data will address a definitive conclusion.
Keywords: rimonabant, Amiotrofic lateral sclerosis, blood calcium
In Press
Case report
Am J Case Rep In Press; DOI: 10.12659/AJCR.946839
Case report
Am J Case Rep In Press; DOI: 10.12659/AJCR.946674
Case report
Am J Case Rep In Press; DOI: 10.12659/AJCR.945853
Case report
Am J Case Rep In Press; DOI: 10.12659/AJCR.947512
Most Viewed Current Articles
21 Jun 2024 : Case report
96,276
DOI :10.12659/AJCR.944371
Am J Case Rep 2024; 25:e944371
07 Mar 2024 : Case report
52,197
DOI :10.12659/AJCR.943133
Am J Case Rep 2024; 25:e943133
20 Nov 2023 : Case report
31,128
DOI :10.12659/AJCR.941424
Am J Case Rep 2023; 24:e941424
18 Feb 2024 : Case report
23,383
DOI :10.12659/AJCR.943030
Am J Case Rep 2024; 25:e943030